awmsg logo



tiotropium (Spiriva® Respimat®)


Reference No. 1526

Publication date:
01/04/2016


Appraisal information

tiotropium (Spiriva® Respimat®) 2.5 micrograms inhalation solution


Company: Boehringer Ingelheim Ltd
BNF category: Respiratory system
NMG meeting date: 09/09/2015
AWMSG meeting date: 24/02/2015
   
   
Submission Type: Full Submission
Status: Not recommended
Advice No: 0516
Ministerial ratification: 30/03/2016

Current Progress


Submission
received
NMG
meeting
AWMSG
meeting
Ministerial
Ratification

AWMSG advice

Tiotropium (Spiriva® Respimat®) is not recommended for use within NHS Wales as an add-on maintenance bronchodilator treatment in adult patients with asthma who are currently treated with the maintenance combination of inhaled corticosteroids (≥ 800 micrograms budesonide daily or equivalent) and long-acting beta2 agonists and who experienced one or more severe exacerbations in the previous year. The company submission did not present sufficient evidence to demonstrate that tiotropium (Spiriva® Respimat®) is cost-effective.
AWMSG Secretariat Appraisal Report (ASAR)
Download
Clinical Expert (CE) Summary
Download
Final Appraisal Recommendation (FAR)
Download